The effectiveness of mebicar in chronic coronary heart disease
- Authors: Kamburg R.A.1, Valimukhametova D.A.1
-
Affiliations:
- Kazan Order of the Red Banner of Labor Medical Institute named after S. V. Kurashov
- Issue: Vol 65, No 6 (1984)
- Pages: 424-426
- Section: Theoretical and clinical medicine
- URL: https://journals.rcsi.science/kazanmedj/article/view/89505
- DOI: https://doi.org/10.17816/kazmj89505
- ID: 89505
Cite item
Full Text
Abstract
Modern pharmacotherapy of chronic coronary heart disease (HIBS) is based on the use of two main groups of drugs — nitrates and beta-blockers. The effectiveness of other drugs in the complex treatment of this disease is being reviewed and constantly debated [1, 2]. The treatment of HIBS, combined with bradycardia, circulatory insufficiency, bronchospastic conditions, intolerance or contraindications to the use of nitrates and beta-blockers, is a great difficulty.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
R. A. Kamburg
Kazan Order of the Red Banner of Labor Medical Institute named after S. V. Kurashov
Author for correspondence.
Email: info@eco-vector.com
Department of Pharmacology, Department of Clinical Pharmacology
Russian Federation, KazanD. A. Valimukhametova
Kazan Order of the Red Banner of Labor Medical Institute named after S. V. Kurashov
Email: info@eco-vector.com
Department of Pharmacology, Department of Clinical Pharmacology
Russian Federation, KazanReferences
